ODT News and Press, Odonate Therapeutics Inc. From 06/26/19

Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced the pricing of an underwritten public offering of 4,750,000 shares of its common stock, offe...

Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced that it has commenced an underwritten public offering of approximately $100 million of share...

InsiderInsights' Daily Round-Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signi...

"I love New York. You can pop out of the Underworld in Central Park, hail a taxi, head down Fifth Avenue with a giant hellhound loping behind you, and nobody even looks at you funny ." - Rick Riordan After May's debacle that saw the overall market plunge by more than six percent, June has...

InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi...

InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi...

Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced that the IDMC for CONTESSA, Odonate’s Phase 3 study investigating tesetaxel as a p...

Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, will present at the Jefferies 2019 Global Healthcare Conference on Wednesday, June 5, 2019, at 2:00 p.m. ...

The following slide deck was published by Odonate Therapeutics, Inc. in conjunction with this Read more ...

Odonate Therapeutics (NASDAQ: ODT ): Q1 GAAP EPS of -$1.16. More news on: Odonate Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...